Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1666089

registered interest
date	19/10/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Cybercrime: Small Businesses
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Science, Innovation and Technology, what recent assessment she has made with Cabinet colleagues on the potential vulnerability of SMEs to cyber-attacks.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	203492
answer	answer is ministerial correction date of answer 25/10/2023 answer text <p>The 2023 <a href="https://www.gov.uk/government/statistics/cyber-security-breaches-survey-2023" target="_blank">Cyber Security Breaches Survey</a> shows 32% of small businesses and 31% of micro businesses identified having suffered a cyber breach or attack in the past 12 months. This is a decline on 2022, however we believe this may be due to smaller businesses deprioritising cyber security and being less likely to identify breaches and attacks, rather than a reduction in the threat.</p><p>Our strategy, working with other relevant Departments and Agencies, is therefore to make it as easy as possible for SMEs to be secure.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/10/2023 15:39:09 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

1541804

registered interest
date	14/11/2022
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Research: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, whether he has made a recent assessment of the potential merits of public sector funding for research and development; and if he will make an assessment of that funding on private sector investment in research and development at all stages of research.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	86489
answer	answer is ministerial correction date of answer 18/11/2022 answer text <p>BEIS has published research by Oxford Economics on the relationship between public and private funding of research and development (R&amp;D) at which estimated the monetary impact of the long-run leverage rate, suggesting that each £1 of public R&amp;D eventually stimulates between £1.96 and £2.34 of private R&amp;D:</p><p><a href="https://www.gov.uk/government/publications/research-and-development-relationship-between-public-and-private-funding" target="_blank">https://www.gov.uk/government/publications/research-and-development-relationship-between-public-and-private-funding</a>.</p><p> </p><p>Public investment in R&amp;D underpins long-term economic growth, is a vital component in our plan for achieving Net Zero and ensures the long-term defence and security of the UK by keeping us at the forefront of technological capabilities. This is why, at the last Spending Review, the Government announced the largest ever sustained uplift in public R&amp;D spending.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 18/11/2022 09:26:21 answering member 4020 label Biography information for George Freeman previous answer version 35259 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

1455226

registered interest
date	29/03/2022
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Research: South Yorkshire
house id	1
legislature	25259 pref label House of Commons
question text	What steps his Department is taking to support research and development in South Yorkshire as part of the Government’s levelling up agenda.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	906355
answer	answer is ministerial correction date of answer 29/03/2022 answer text <p>We are growing R&amp;D clusters around the country and I recently had the pleasure of visiting the BioYorkshire cluster. The Levelling Up White Paper set a new mission to increase domestic public investment in R&amp;D outside the Greater South East by at least one third over the Spending Review period and at least 40 percent by 2030.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/03/2022 11:56:26 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

1146779

registered interest
date	27/09/2019
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Roads
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Transport, what steps his Department is taking to improve road connectivity between South Yorkshire and Greater Manchester.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	291576
answer	answer is ministerial correction date of answer 07/10/2019 answer text <p>The first Road Investment Strategy committed to an investment package worth over £170 million for existing Sheffield-Manchester connections to address safety and congestion issues, and improve journey times. Highways England has announced a preferred route which covers the:</p><ul><li><p>Mottram Moor link road;</p></li><li><p>A57(T) to A57 link road;</p></li><li><p>A616/A61(T) Westwood roundabout; and,</p></li><li><p>Safety and technology improvements along the route.</p></li></ul><p>The Department for Transport, in conjunction with Highways England and Transport for the North, is undertaking a study looking at the long term strategic road connection requirements to link the areas of Greater Manchester and South Yorkshire to transform journeys and enhance connectivity across the southern Pennines. This includes consideration of a trans-Pennine tunnel. The study is expected to report in spring 2020.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/10/2019 12:32:37 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

520803

registered interest
date	23/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if his Department will take steps to ensure that the proposals to more closely align the approval process for the new cancer drugs fund with the National Institute for Health and Care Excellence do not limit access to potential life-saving treatments such as Avastin for the treatment of ovarian cancer.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	37866
answer	answer is ministerial correction date of answer 26/05/2016 answer text <p>Since October 2010, the Cancer Drugs Fund (CDF) has helped over 84,000 people in England in accessing life-extending cancer drugs that would not otherwise have been available to them.</p><p> </p><p>NHS England is responsible for the operational management of the Fund and has consulted, jointly with the National Institute for Health and Care Excellence, on new arrangements for the CDF which will go live on 1 July 2016.</p><p> </p><p>NHS England has advised that, under these new arrangements, it envisages that a greater number of cancer drugs will be funded from baseline commissioning. This will be as a consequence of more appropriate pricing arrangements proposed by pharmaceutical manufacturers and better evidence being available through the Fund as to longer term patient outcomes.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 26/05/2016 13:49:23 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

520808

registered interest
date	23/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the effect of the Cystic Fibrosis Trust's proposal for collaboration between the NHS and Vertex to widen access to the treatment Orkambi on the treatment of the patients with that disease.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	37867
answer	answer is ministerial correction date of answer 26/05/2016 answer text <p>The Department has received the Cystic Fibrosis Trust’s proposals for an arrangement that would potentially allow access to Orkambi (lumacaftor in combination with ivacaftor) as part of a Managed Access Scheme in the National Institute for Health and Care Excellence’s (NICE) appraisal of Orkambi.</p><p> </p><p>I have encouraged the Trust and the manufacturer, Vertex Pharmaceuticals, to engage with NICE to consider whether there remains scope for this, or any other, proposal to be taken into account in its appraisal and the Department is also engaging with the manufacturer directly on this matter.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 26/05/2016 14:12:46 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

424318

registered interest
date	27/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Disability: Genetics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his Department has on (a) raising awareness of severe and complex disabilities suspected of having a genetic syndrome for which it is not currently possible to confirm a diagnosis and (b) helping to ensure that patients and their families that are affected by such disabilities have access to appropriate care and support.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	13735
answer	answer is ministerial correction date of answer 04/11/2015 answer text <p>The Department is committed to improving the diagnosis and treatment of rare diseases, including those severe and complex conditions caused by genetic disorders, through implementation of the UK Strategy for Rare Diseases, published in November 2013. The UK strategy includes specific recommendations to improve awareness amongst service providers and others of the effects that rare diseases can have on a person’s education, family, social relationships and ability to work. There is also a specific recommendation to improve education and awareness across the healthcare professions and to improve the co-ordination of care, recognising that some patients have complex needs and require expertise from a number of specialists and carers.</p><br /><p>The UK Rare Disease Forum will monitor progress against the recommendations in the strategy and is due to produce its first report in early 2016.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/11/2015 17:07:17 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

422643

registered interest
date	20/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Rare Diseases: Diagnosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what change there has been in the rate of undiagnosed diseases in the last five years; and if his Department will continue to fund at the present rate research into undiagnosed diseases.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	12566
answer	answer is ministerial correction date of answer 28/10/2015 answer text <p>Data on the numbers of undiagnosed diseases is not held centrally. The Department is committed to improving the diagnosis of rare diseases through the UK Strategy for Rare Diseases. This includes commitments to reduce times for diagnosis and to establish appropriate diagnostic pathways which are accessible to and understood by, healthcare professionals and patients.</p><br /><p>The Department has commissioned research into the diagnostic odyssey for rare diseases to improve the measurement of rates of diagnosis. The Policy and Innovation Research Unit published the report Diagnostic Odyssey for Rare Diseases, Exploration of Potential Indicators in April 2015 (<a href="http://www.piru.ac.uk/" target="_blank">www.piru.ac.uk</a>).</p><br /><p>The Government is making substantial investment in infrastructure for research into rare diseases through the National Institute for Health Research. A total of over £800 million has been invested in Biomedical Research Centres and Units and a further £100 million in funding to support Clinical Research Facilities for experimental medicine. The Prime Minister’s 100,000 Genomes project is also focussing on rare diseases and has already led to a diagnosis for some patients who were unable to find a diagnosis through existing NHS tests.</p><br /> <br /> <br /> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/10/2015 17:13:43 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

383903

registered interest
date	18/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Everolimus: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans he has to provide funding for everolimus.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	3075
answer	answer is ministerial correction date of answer 23/06/2015 answer text <p>It is for National Health Service commissioners to make funding decisions on individual treatments taking into account guidance from the National Institute for Health and Care Excellence (NICE) where available. Cancer drugs that are not routinely funded by the NHS may be available through the Cancer Drugs Fund.</p><p> </p><p> </p><p> </p><p>Everolimus is available through the Cancer Drugs Fund for two indications: (i) in combination with exemestane, for advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy and (ii) for the second-line treatment of advanced renal cell carcinoma.</p><p> </p><p> </p><p> </p><p>Everolimus is currently being appraised by NICE for the prevention of organ rejection in liver transplantation and for use in renal transplantation.</p><p> </p><p> </p><p> </p><p>Everolimus is also licensed for use in the treatment of Tuberous Sclerosis and Subependymal Giant Cell Astrocytoma (SEGA). NICE has not been asked to develop guidance on the use of everolimus for these conditions. It is therefore for NHS commissioners to take funding decisions based on an assessment of the available evidence.</p><p> </p><p> </p><p> </p><p>In January this year, NHS England launched a three-month public consultation to seek people’s views about proposals for a set of principles which NHS England should apply when making investment decisions and a new process for developing commissioning policies for specific treatments, drugs and medical devices. These elements are part of a Framework, which, when finalised, will underpin every decision NHS England makes about specialised services investments.</p><p> </p><p> </p><p> </p><p>Now that the consultation has ended, NHS England has advised that work is underway to determine whether any amendments are required to its proposals as a result of the feedback received.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 23/06/2015 10:15:27 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

170452

registered interest
date	15/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Licensing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with clinicians about how to improve the uptake of clinically and cost-effective off-patent drugs outside their licensed indications.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	218685
answer	answer is ministerial correction date of answer 18/12/2014 answer text <p>We have had no detailed discussions but we are holding a roundtable stakeholder event in the new year where we will discuss a number of issues raised by the Off-Patent Drugs Bill. Individual prescribing decisions on the most appropriate treatments are a matter for clinicians, in discussion with their patients.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 18/12/2014 15:44:54 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis